OCUGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 USD | +8.47% |
|
-3.03% | +122.61% |
| Apr. 22 | Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating | MT |
| Apr. 22 | Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating | MT |
Presenter SpeechShankar Musunuri (Executives)Good morning. Thank you for coming to Ocugen Clin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Calendar
2024-05-02
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.28
USD
Average target price
6.667
USD
Spread / Average Target
+420.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +122.61% | 329M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Transcript : Ocugen, Inc. - Special Call
